- The 8 States Most Likely to Legalize Marijuana Next
- Behind Russia's Current Crisis: It's Not the Ruble, It's Putin
- Would you invest in the U.S. Postal Service?
- Why Jim Cramer Says it Could be Too Late to Enter the Stock Market Rally Now
- Apple (AAPL) Stock Declining Today Amid Allegations of Poor Working Conditions in China
The power to control drug prices in the U.S. now has shifted firmly to cost-cutting insurance carriers and pharmacy benefit managers and away from biotech and drug companies.
U.S. regulators approved a new hepatitis C therapy from Abbvie, heralding a new era of market competition with Gilead Sciences.
Good calls: Vertex, InterMune, Chelsea, Galena, Exact Sciences. The bad calls: Avanir, Amarin, Exelixis and the bursting biotech stock bubble.
European regulators recommended the approval of Orexigen Therapeutics weight-loss pill on Friday, opening a new commercial market opportunity closed off to the company's competitors.
Congrats to David Schenkein of Agios and Nick Leschly of Bluebird Bio for snagging 'Best' honors, while the ignominious (dis)honor of 'Worst' goes to Martin Shkreli, formerly of Retrophin.
To prep investors for 2015, a list of clinical trial read-outs and FDA events expected to have a significant impact on stock prices in the first half of next year.
Auspex is expected to seek U.S. approval for SD-809 next year.
One biotech CEO won accolades in 2010 only to be razzed for poor performance in 2011.
The CEOs of Aegerion, Dendron, CytRx, Galena, Repros, Northwest Bio and Retrophin deserve jeers for their performances this year, but who's the worst of the bunch?
Tony Coles, the former CEO of Onyx sold to Amgen for $10 billion in late 2013, is launching Yumanity Therapeutics focused on developing drugs for neuro-degenerative diseases.